Furthermore, in a pooled analysis of 57 studies (with a total of 2528 patients), we found a global prevalence of 30% of abnormal p53 in G3 endometrioid endometrial carcinoma. This evidence concerns the gene TP53 and endometrial endometrioid carcinoma.